Monte Rosa Therapeutics
@monterosatx.com
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more.
Conference call and webcast presentation today, January 7, 2026, at 8:00 a.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website. bit.ly/4qa3m3d
January 7, 2026 at 12:14 PM
Conference call and webcast presentation today, January 7, 2026, at 8:00 a.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website. bit.ly/4qa3m3d
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
January 6, 2026 at 1:48 PM
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
December 22, 2025 at 1:10 PM
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.
December 18, 2025 at 12:59 PM
This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.
Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC.
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
December 16, 2025 at 12:31 PM
Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC.
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
We will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, December 16 to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients.
Access the webcast here: bit.ly/3KSVjbQ
Access the webcast here: bit.ly/3KSVjbQ
December 15, 2025 at 9:36 PM
We will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, December 16 to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients.
Access the webcast here: bit.ly/3KSVjbQ
Access the webcast here: bit.ly/3KSVjbQ
Our colleagues break down the work behind this year’s Science Magazine cover story and what it means for the future of molecular glue degrader (MGD) development:
bit.ly/3KvGUlL
bit.ly/3KvGUlL
December 10, 2025 at 1:38 PM
Our colleagues break down the work behind this year’s Science Magazine cover story and what it means for the future of molecular glue degrader (MGD) development:
bit.ly/3KvGUlL
bit.ly/3KvGUlL
Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism.
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
November 19, 2025 at 3:28 PM
Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism.
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk